Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration‐resistant Prostate Cancer Undergoing Hemodialysis
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2018.12.004
Abstract: Enzalutamide is a well-established treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, for patients with end-stage renal disease, no pharmacokinetic data is available. Therefore, we present a case of a patient with… read more here.
Keywords: hemodialysis; levels enzalutamide; undergoing hemodialysis; cancer ... See more keywords